Food and Drug Administration allows the use of Abilify MyCite
Is there a way for doctors to determine whether patients have really taken all of the prescribed medication? A tablet has now been approved in the USA that reports its digestion in the stomach and then forwards the data to a cloud.
The experts from the US Food and Drug Administration (FDA) have now approved a tablet and accessories for the first time. This tablet contains a tiny sensor, which then emits an electrical pulse when it comes into contact with the stomach acid. A special patch on the affected patient registers this signal and automatically forwards the information to an app. From there, the data goes to the cloud. The FDA released a press release approving the tablet.
The tablet and accessories have already been approved by the FDA
The US drug agency FDA has now approved a tablet and accessories for the first time, in which a sensor system reports when the tablet comes into contact with stomach acid. For example, data subjects can document and track when they took their tablets. It is also possible for physicians and nurses to access the data - of course only with the consent of the patient concerned.
Abilify MyCite is used for schizophrenia and bipolar disorders
The drug called Abilify MyCite is used in various diseases. It can be used to treat schizophrenia and bipolar disorders, for example. The tablet can also be prescribed to accompany severe depression.
Which company makes the tablet?
The manufacturer of the new tablet is a Japanese company called Otsuka Pharmaceutical. This company has been selling tablets containing the active ingredient aripiprazole for years. The sensor used is manufactured by the US company Proteus Digital Health.
Some people do not take their medication in manic phases
Especially in the case of a mental illness, it can be very important that the exact intake of the prescribed tablets is observed. For example, some people with bipolar disorder have the problem that they stop taking their medication when they are in a manic phase of the disease. "For some patients, it might make sense to keep an eye on tablets for mental illnesses," explains Dr. Mitchell Mathis from the FDA.
Assumption of costs by insurance has not yet been clarified
So far, it has not been clarified whether the use of the new technology also helps patients take their medication more regularly, the manufacturers of the tablet and the US drug agency FDA explain. It also remains unclear whether insurance companies will cover the costs of the newly developed drug. The assumption of costs could possibly be refused until there is clear evidence of increased adherence to therapy through monitoring with the tablet, the experts explain.
Treatment of diabetes or high blood pressure with Abilify MyCite in the future?
The manufacturer Proteus Digital Health is apparently already planning to make the tablet available to a much larger target group. Researchers believe that the tablet monitoring system could have a massive impact on the treatment of patients with diabetes or high blood pressure. This could be extremely important with the increasing number of hypertensive patients. (as)